BML (4694) AI Stock Analysis

• Market Cap: €135.37B
• Dividend Yield: 3.17%
• Average Volume (3M): 54.09K
• Price to Earnings (P/E): 22.0
• Beta (1Y): 0.45
• Revenue Growth: 5.90%
• EPS Growth: 16.30%
• Country: JP
• Employees: 4,513
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 61.63
• Shares Outstanding: 40,749,428
• 10 Day Avg. Volume: 38,460
• 30 Day Avg. Volume: 54,093
• PEG Ratio: 4.96
• Price to Book (P/B): 0.91
• Price to Sales (P/S): 0.82
• P/FCF Ratio: 177.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: ¥4,095.00 ▲(7.62% Upside)

BML's strong financial performance and positive technical indicators are the primary drivers of its stock score. The company's robust balance sheet and profitability metrics provide a solid foundation, while technical analysis suggests a positive market trend. The valuation is reasonable, with a moderate P/E ratio and attractive dividend yield. However, declining revenue and fluctuating cash flow present potential risks.

Positive Factors

Business Model Strength

The subscription-based model ensures recurring revenue, providing financial stability and predictability, which supports long-term growth.

Partnerships and Collaborations

Strategic partnerships enhance market reach and service offerings, strengthening BML's competitive position and driving sustainable growth.

Balance Sheet Health

A strong balance sheet with low leverage provides financial stability and flexibility, enabling BML to invest in growth opportunities.

Negative Factors

Declining Revenue

Revenue decline poses a risk to future growth, potentially impacting BML's ability to invest in innovation and maintain competitive advantage.

Fluctuating Free Cash Flow

Volatility in free cash flow can hinder consistent capital allocation, affecting BML's capacity to fund strategic initiatives and manage financial obligations.

Decreased Operational Efficiency

Decreasing margins suggest challenges in maintaining operational efficiency, which could pressure profitability and limit reinvestment in business growth.

BML Business Overview & Revenue Model

Company Description

BML, Inc. provides laboratory testing and related services in Japan. The company offers general laboratory tests, including biochemical and hematologic examinations; special laboratory tests, such as RIA, cellular, immunological, and DNA analysis; microbiological tests for medical and pharmaceutical societies and organizations; and laboratory tests in tumorology, infectious disease, diabetes, hypertension, allergy, and genetic studies. It also develops Frontier and Symphony automation systems, which automate pre-processing procedures from sorting to dispensing, and subsequent test procedures; and provides electronic medical charts for networking medical information, as well as offers preventive medicine services. In addition, the company provides food sanitation control and food processing services comprising contract services for microorganism testing of raw materials, and prepared and processed foods; environmental hygiene testing of food processing facilities and kitchens; and microorganism testing services, as well as assesses genetically modified organisms. Further, it provides drinking water and waste water tests; work sanitation management services, such as measurement of ethylene oxide gas, formaldehyde, organic solvents, and dust; environmental monitoring services, including measurement of indoor contaminants and other indoor environmental variables; and biological dioxin monitoring services. Additionally, the company offers analysis services for residual agricultural chemicals; dental test services for dental caries and periodontal diseases; consulting services for the approval of pharmaceuticals; investigative analysis services to pharmaceutical manufacturers; and gene expression analysis and testing for genes that cause susceptibility to infectious diseases. BML, Inc. was founded in 1955 and is headquartered in Tokyo, Japan.

How the Company Makes Money

BML generates revenue primarily through a subscription-based model for its software solutions, which includes recurring fees for cloud services and maintenance. Additionally, the company earns income from consulting services that assist clients in implementing and optimizing technology solutions. Key revenue streams include licensing fees for proprietary software, project-based consulting contracts, and partnerships with other tech firms that facilitate joint offerings. Significant collaborations with major cloud service providers also contribute to BML's earnings by expanding its market reach and enhancing service offerings.

BML Financial Statement Overview

Summary

BML exhibits strong profitability indicators with a consistent gross profit margin and a healthy net profit margin. The company maintains a robust balance sheet with a strong equity base and low debt-to-equity ratio, indicating financial stability. However, declining revenue and fluctuating free cash flow could pose future challenges.

Income Statement

BML exhibits strong profitability indicators with a consistent gross profit margin and a healthy net profit margin, reflecting effective cost management and strong revenue generation. However, the company has experienced a decline in revenue over recent years, which could be a concern for future growth. The EBIT and EBITDA margins indicate efficient operations, although they have decreased from prior years, suggesting room for improving operational efficiency.

Balance Sheet

BML maintains a robust balance sheet with a strong equity base and a low debt-to-equity ratio, indicating financial stability and a low risk of financial distress. The equity ratio suggests strong capitalization, providing a solid buffer against liabilities. The return on equity has remained healthy, showcasing efficient use of shareholders' funds despite a decrease in net income in recent periods.

Cash Flow

BML's cash flow management appears stable, with positive operating cash flow supporting its operations. However, free cash flow has fluctuated significantly, pointing to potential volatility in capital expenditures and investment activities. The operating cash flow to net income ratio demonstrates the company's ability to convert income into cash, although the volatility in free cash flow indicates potential challenges in maintaining consistent cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	145.63B	143.19B	137.96B	159.46B	186.07B	138.57B
Gross Profit	46.42B	45.86B	45.63B	61.45B	86.95B	54.77B
EBITDA	18.27B	17.51B	16.42B	30.57B	56.26B	26.50B
Net Income	6.42B	6.26B	6.03B	15.58B	33.74B	13.71B
Balance Sheet
Total Assets	175.54B	177.51B	170.99B	168.94B	179.20B	139.17B
Cash, Cash Equivalents and Short-Term Investments	65.46B	67.56B	74.11B	86.52B	92.13B	63.48B
Total Debt	4.29B	5.29B	5.26B	4.15B	5.44B	5.39B
Total Liabilities	42.81B	43.73B	40.85B	42.20B	57.52B	46.05B
Stockholders Equity	128.46B	129.40B	125.86B	122.49B	116.20B	88.42B
Cash Flow
Free Cash Flow	0.00	663.00M	-6.48B	5.28B	38.52B	15.38B
Operating Cash Flow	0.00	15.81B	14.45B	11.74B	45.60B	19.57B
Investing Cash Flow	0.00	-16.79B	-21.14B	-7.63B	-7.30B	-4.58B
Financing Cash Flow	0.00	-5.43B	-5.73B	-9.71B	-9.83B	-3.38B

BML Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3805.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4694, the sentiment is Positive. The current price of 3805 is above the 20-day moving average (MA) of 3685.25, above the 50-day MA of 3652.08, and above the 200-day MA of 3221.86, indicating a bullish trend. The MACD of 41.57 indicates Negative momentum. The RSI at 60.86 is Neutral, neither overbought nor oversold. The STOCH value of 81.66 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4694.

BML Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4694	74 Outperform	€135.37B	22.00	5.59%	3.17%	5.90%	16.30%
4671	73 Outperform	¥25.02B	13.21	―	5.00%	1.23%	9.96%
2395	69 Neutral	¥72.61B	15.60	―	3.34%	28.06%	19.48%
4886	67 Neutral	¥56.26B	12.58	―	2.46%	5.44%	-20.33%
4549	66 Neutral	¥81.83B	21.20	―	2.38%	4.36%	79.43%
4544	62 Neutral	¥208.38B	54.76	2.65%	3.42%	2.93%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

BML Corporate Events

BML Completes Treasury Shares Disposal for Stock Compensation

BML, Inc. has completed the payment procedures for the disposal of its treasury shares as restricted stock compensation, a decision made in a board meeting on July 25, 2025. This disposal involves 20,190 shares of common stock at a price of 3,490 yen per share, totaling 70,463,100 yen, and is allocated to directors and executive officers of the company, potentially impacting the company’s equity structure and aligning management incentives with shareholder interests.

The most recent analyst rating on (JP:4694) stock is a Buy with a Yen3826.00 price target. To see the full list of analyst forecasts on BML stock, see the JP:4694 Stock Forecast page.

BML Completes Treasury Share Acquisition and Plans Cancellation

BML, Inc. has completed the acquisition of 1,545,000 treasury shares, representing 4.0% of its total issued shares, through the ToSTNeT-3 trading system. This move aims to enhance capital efficiency and improve shareholder returns, with a scheduled cancellation of these shares set for September 12, 2025, reflecting a strategic effort to optimize the company’s financial structure.

BML, Inc. Announces Strategic Share Buyback and Cancellation

BML, Inc. announced its decision to acquire and subsequently cancel its own shares to enhance capital efficiency and improve shareholder returns. The acquisition will be executed through the Tokyo Stock Exchange’s off-auction trading system at a specified price, with a maximum of 1,700,000 shares to be acquired. This strategic move is expected to positively impact the company’s financial structure and shareholder value.

BML, Inc. Reports Strong Q1 Fiscal 2025 Results with Positive Growth

BML, Inc. reported a positive financial performance for the first quarter of fiscal 2025, with net sales increasing by 6.8% and operating profit rising by 10.1% compared to the same period last year. The company’s strong results reflect its effective market strategies and operational efficiencies, positioning it well in the healthcare industry. The financial outlook for the full fiscal year anticipates a modest growth in net sales, although a slight decline in profits is expected, indicating potential challenges ahead.